Elicio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. on January 16, 2024. The report details an update regarding the Company's At-The-Market (ATM) Equity Offering Program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed relates to the ATM program:
- Shares Sold: 584,170 shares of common stock issued since the quarter ended September 30, 2023.
- Net Proceeds: Approximately $4.89 million (after deducting sales commissions).
- Program Capacity: The original agreement allows for aggregate sales of up to $21.0 million.
Material Changes
The material change reported is the execution of sales under the existing ATM agreement with Stifel, Nicolaus & Company, Incorporated and Virtu Americas LLC. The filing does not provide comparative data against prior periods for these specific sales activities.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity offering. The document focuses solely on the transactional update of the ATM program.
Investor Verification Checklist
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the remaining aggregate offering price available under the $21.0 million ATM agreement.
- Review the most recent 10-Q or 10-K for comprehensive liquidity and cash position data, as this 8-K does not provide a full balance sheet.